Seminars in Oncology
Volume 36 , Pages S25-S34 , August 2009

Should Intra-cerebrospinal Fluid Prophylaxis Be Part of Initial Therapy for Patients With Non-Hodgkin Lymphoma: What We Know, and How We Can Find Out More

  • Ulrich Herrlinger

      Affiliations

    • Division of Clinical Neuro-oncology, Department of Neurology, University of Bonn, Bonn, Germany
    • Corresponding Author InformationAddress correspondence to Ulrich Herrlinger, MD, Division of Clinical Neuro-oncology, Department of Neurology, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany
    • ,
  • Michael Glantz

      Affiliations

    • Department of Neurosurgery, Penn State Hershey Medical Center, Hershey, PA
    • ,
  • Uwe Schlegel

      Affiliations

    • Department of Neurology, Knappschaftskrankenhaus, Bochum, Germany
    • ,
  • Christian Gisselbrecht

      Affiliations

    • Hematology Institute, Saint-Louis Hospital, Paris, France
    • ,
  • Franco Cavalli

      Affiliations

    • Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

References 

  1. Bashir RM, Bierman PJ, Vose JM, Weisenburger DD, Armitage JO. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol. 1991;14:478–482
  2. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin M, Sankatsing SU, et al. Central nervous system relapse in non-Hodgkin lymphoma: a single-center study of 532 patients. Arch Neurol. 1997;54:854–859
  3. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91:1178–1184
  4. Zinzani PL, Magagnoli M, Frezza G, Prologo G, Gherlinzoni F, Bendandi M, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma. 1999;32:571–576
  5. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18:149–157
  6. Haioun C, Besson C, Lepage E, Thieblemont C, Simon D, Rose C, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients (Groupe d'Etudes des Lymphomes de l'Adulte). Ann Oncol. 2000;11:685–690
  7. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol. 2002;13:1099–1107
  8. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15:129–133
  9. Herman TS, Hammond N, Jones SE, Butler JJ, Byrne GE, McKelvey EM. Involvement of the central nervous system by non-Hodgkin's lymphoma: the Southwest Oncology Group experience. Cancer. 1979;43:390–397
  10. Recht L, Straus DJ, Cirrincione C, Thaler HT, Posner JB. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med. 1988;84:425–435
  11. Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A Dutch HOVON Group. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory?. Ann Oncol. 1998;9:191–194
  12. Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516—Southwest Oncology Group. J Clin Oncol. 2009;27:114–119
  13. Fischer L, Jahnke K, Martus P, Weller M, Thiel E, Korfel A. The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. Haematologica. 2006;91:429–430
  14. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496–502
  15. Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma—a multivariate analysis. Acta Oncol. 1996;35:703–708
  16. Liang RH, Woo EK, Yu YL, Todd D, Chan TK, Ho FC, et al. Central nervous system involvement in non-Hodgkin's lymphoma. Eur J Cancer Clin Oncol. 1989;25:703–710
  17. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006;20:319–332
  18. Tomita N, Kodama F, Sakai R, Koharasawa H, Hattori M, Taguchi J, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma. 2000;38:335–343
  19. Freund M, Ostendorf P, Gartner VH, Waller HD. CNS manifestations in non-Hodgkin lymphomas (NHL). Klin Wochenschr. 1983;61:903–909
  20. Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in the non-Hodgkin's lymphomas. Cancer. 1980;45:545–552
  21. Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986;4:847–858
  22. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–3020
  23. Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100:1438–1448
  24. Haddy TB, Adde MA, Magrath IT. CNS involvement in small noncleaved-cell lymphoma: is CNS disease per se a poor prognostic sign?. J Clin Oncol. 1991;9:1973–1982
  25. Kujawski LA, Longo WL, Williams EC, Turman NJ, Brandt N, Mosher DF, et al. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest. 2007;25:87–93
  26. Litam JP, Cabanillas F, Smith TL, Bodey GP, Freireich EJ. Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood. 1979;54:1249–1257
  27. Johnson GJ, Oken MM, Anderson JR, O'Connell MJ, Glick JH. Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: is prophylaxis indicated?. Lancet. 1984;2:685–687
  28. Ersboll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol. 1985;35:487–496
  29. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102:4284–4289
  30. Björkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol. 2007;18:1085–1089
  31. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116
  32. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol. 2005;131:193–200
  33. Buckstein R, Lim W, Franssen E, Imrie KL. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma. 2003;44:955–962
  34. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21:1044–1049
  35. Fine HA. Primary central nervous system lymphoma: time to ask the question. J Clin Oncol. 2002;20:4615–4617
  36. Larocca LM, Capello D, Rinelli A, Nori S, Antinori A, Gloghini A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood. 1998;92:1011–1019
  37. Kuker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72:169–177
  38. Fisher R, Glantz MJ, Blummenthal D, Batten J, Van Horn A, Chalmers L, et al. Phase II trial of high-dose intravenous methotrexate (MTX) and rituximab with or without intraventricular DepoCyt in patients with newly diagnosed primary central nervous system lymphoma (PCNSL) [abstract TA-16]. Neurooncol. 2006;8:441
  39. Herrlinger U, Korfel A, Hebart H, Schlegel U, Plasswilm L, Illerhaus G, et al. Meeting report: primary central nervous system lymphoma: standards of care and future perspectives. Onkologie. 2005;28:109–111
  40. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10:635–643
  41. Hiraga S, Arita N, Ohnishi T, Kohmura E, Yamamoto K, Oku Y, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg. 1999;91:221–230
  42. O'Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000;18:519–526
  43. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144–3150
  44. Ferreri AJ, Reni M, Dell'Oro S, Ciceri F, Bernardi M, Camba L, et al. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Oncology. 2001;60:134–140
  45. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group study 93-10. J Clin Oncol. 2002;20:4643–4648
  46. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol. 1999;43:241–247
  47. Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol. 1998;16:3000–3006
  48. McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery. 2000;46:51–60
  49. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kuker W, Deckert M, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol. 2002;51:247–252
  50. Herrlinger U, Kuker W, Uhl M, Blaicher HP, Karnath HO, Kanz L, et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol. 2005;57:843–847
  51. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol. 1999;16:1561–1567
  52. Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma. Neurosurg Focus. 2006;21:E12
  53. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol. 1999;43:259–268
  54. Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry. 2001;71:118–122
  55. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489–4495
  56. Bleyer WA, Poplack DG, Simon RM. “Concentration × time” methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood. 1978;51:835–842
  57. Obbens EA, Leavens ME, Beal JW, Lee YY. Ommaya reservoirs in 387 cancer patients: a 15-year experience. Neurology. 1985;35:1274–1278
  58. Perrin RG, Lishner M, Guha A, Curtis J, Feld R, Messner H. Experience with Ommaya reservoir in 120 consecutive patients with meningeal malignancy. Can J Neurol Sci. 1990;17:190–192
  59. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58:1513–1520
  60. Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol. 2002;58:175–178
  61. Pels H, Jurgens H, Glasmacher A, Schulz H, Vogt-Schaden M, Lamprecht M, et al. Modified “Bonn protocol” without intraventricular chemotherapy in the treatment of primary CNS lymphoma: preliminary results [abstract 024]. Neurooncol. 2006;8:293–372
  62. Juergens A, Pels H, Schlegel U, Schmidt-Wolf IGH, Glasmacher A, Schulz H, et al. Primary central nervous system lymphoma: results of a pilot phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy—final report [abstract O95]. J Neurol. 2006;253;Suppl 2:II/23
  63. Ferreri AJ, Reni M. Establishing a prognostic score for primary CNS lymphomas. Int J Radiat Oncol Biol Phys. 2005;61:303–304
  64. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer. 2002;95:576–580
  65. Chamberlain MC. Neoplastic meningitis. Neurologist. 2006;12:179–187
  66. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5:443–452
  67. Bleyer WA. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium. Clin Cancer Res. 1999;5:3349–3351
  68. Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther. 1984;35:826–830
  69. Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol. 2007;81:201–208
  70. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–3116

 STATEMENT OF CONFLICT OF INTEREST: U.H. received speakers and advisory honoraria from Mundipharma. M.G. has received honoraria and research support from Enzon Pharmaceuticals. The other authors have nothing to disclose.

PII: S0093-7754(09)00094-3

doi: 10.1053/j.seminoncol.2009.05.004

Seminars in Oncology
Volume 36 , Pages S25-S34 , August 2009

Article Tools